TC-A101 / TCRCure, Xinqiao Hospital - LARVOL DELTA

Engineered T-cell Therapy for Patients With ALPP-Positive Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=5 | Terminated | Sponsor: TCRCure Biopharma Ltd. | N=24 ➔ 5 | Trial completion date: Aug 2027 ➔ Jan 2026 | Recruiting ➔ Terminated | Trial primary completion date: Aug 2026 ➔ Dec 2025; Portfolio prioritization

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Solid Tumor

Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=5 | Completed | Sponsor: Xinqiao Hospital of Chongqing | Recruiting ➔ Completed | N=20 ➔ 5 | Trial completion date: May 2025 ➔ Aug 2025

Enrollment change • Trial completion • Trial completion date • Solid Tumor • MSLN

Engineered T-cell Therapy for Patients With ALPP-Positive Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: TCRCure Biopharma Ltd.

New P1 trial • Solid Tumor

Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=20 | Recruiting | Sponsor: Xinqiao Hospital of Chongqing | Suspended ➔ Recruiting

CAR T-Cell Therapy • Enrollment open • Metastases • Oncology • Solid Tumor • MSLN

Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=20 | Suspended | Sponsor: Xinqiao Hospital of Chongqing | Recruiting ➔ Suspended

Trial suspension • Oncology • Solid Tumor • MSLN

Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=20 | Recruiting | Sponsor: Xinqiao Hospital of Chongqing | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2023 ➔ May 2025 | Trial primary completion date: Dec 2022 ➔ Dec 2024

CAR T-Cell Therapy • Enrollment open • Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor • MSLN

Anti-ALPP CAR-T Cell Immunotherapy for Ovarian and Endometrial Cancer (SITC 2022) - "Conclusions The preclinical findings reported here indicate that ALPP could be a good target and anti-ALPP CAR-T cell immunotherapy is potentially safe and efficacious against female reproductive cancers expressing ALPP. Ethics Approval All in vivo experiments in this study were conducted according to guidelines under a protocol approved by Mispro Biotech Services Institutional Animal Care and Use Committee."

CAR T-Cell Therapy • IO biomarker • Endometrial Cancer • Oncology • Ovarian Cancer • Solid Tumor • ALPP

First-in-human anti-ALPP CAR-T cell immunotherapy for ovarian and endometrial cancer (ESMO 2022) - P1/2 | "We observed objective tumor regression in two of these three patients, with one patient reaching the threshold of partial response. Conclusions The preclinical and initial clinical findings reported here indicate that TC-A101 T cell immunotherapy is safe and potentially efficacious against female reproductive cancers expressing ALPP."

CAR T-Cell Therapy • IO biomarker • P1 data • Endometrial Cancer • Oncology • Ovarian Cancer • Solid Tumor • ALPP